[go: up one dir, main page]

WO2023015102A1 - Procédé de production d'isolat de cbd - Google Patents

Procédé de production d'isolat de cbd Download PDF

Info

Publication number
WO2023015102A1
WO2023015102A1 PCT/US2022/073669 US2022073669W WO2023015102A1 WO 2023015102 A1 WO2023015102 A1 WO 2023015102A1 US 2022073669 W US2022073669 W US 2022073669W WO 2023015102 A1 WO2023015102 A1 WO 2023015102A1
Authority
WO
WIPO (PCT)
Prior art keywords
vessel
measure
temperature
approximately
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/073669
Other languages
English (en)
Inventor
Duane DRINKWINE
Donal R. SCHMIDT
Sean P. BERRIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rapid Therapeutic Sciences Laboratories Inc
Original Assignee
Rapid Therapeutic Sciences Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapid Therapeutic Sciences Laboratories Inc filed Critical Rapid Therapeutic Sciences Laboratories Inc
Publication of WO2023015102A1 publication Critical patent/WO2023015102A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol

Definitions

  • the background of the invention relates to metered dose, inhaler-related products, formulations, and methods of manufacturing.
  • the inventors seek to provide, vis-a-vis prior methods, formulations and administrative devices, improved methods of formulation and associated optimal delivery means associated with the therapeutic use of cannabidiol (CBD).
  • CBD cannabidiol
  • CBD is known to be a therapeutic agent, inter alia, in the realm of remediation of pain.
  • An optimal mode of administration involves the use of atomizing inhalers. Integration of CBD and inhalers, utilizing currently known methods and formulations, manifest a number of significant shortcomings with respect to each of efficacious administration as well as both avoidance of adulteration and reasonable shelf life of all presently known inhaler-contained, to-be-administered CBD formulations.
  • inhaler-based CBD products are, by their formulations, manufacturing methodologies and post-production age by the time of their use, less efficacious that the present inventors have determined that CBD products otherwise could be, elicit unpleasant side-effects for users, and fail even to meet regulatory product adulteration standards.
  • CBD cannabidiol
  • the present inventors here disclose a novel and unobvious crystallization process to efficiently produce pH-balanced CBD in an oxygen-free environment that is optimally delivered in a metered-dose inhaler, without re-engineering the typical droplet size which is otherwise essential in the efficacious use of any systemic inhaler.
  • the process of the present invention is a crystallization work-up that creates a more properly balance pH/CBD isolate for use into an RTSL inhaler.
  • the present inventors have, through extensive research and testing, developed a CBD formulation and manufacturing process that addresses each of the above-described shortcoming of the present art.
  • the optimal steps in the here disclosed CBD product formulation methodology include:
  • the next step is the addition of a high temperature Hemp distillate. a. Note: The Hemp distillate must be greater than 80% CBD by volume.
  • Total % of Hemp Distillate will depend on maximum working volume of the JFR -20% working volume and -33% of n- Pentane for every 1 Kg of distillate and/or the amount of available material into the main body of the JFR).
  • the Huber Ministat 230 TCS is used for a 5L APICAL Filter reactor. Then set the TCS to 30° C to cool the jacket of the JFR. After 30° C is achieved, let agitate for -15 minutes. Next, mix 1 gram of potassium carbonate (K2CO3) with 2 grams of filter distilled water (D/H2O) by weight in a separate beaker until all the potassium is dissolved. Add the mixture into the main body of the JFR. a. Note: None add D/H2O or K2CO3 directly to the aqueous mixture without dissolving the K2CO3 in D/H2O. Agitate the homogenous solution for 15 to 20 minutes. Check for a pH value of 6 to 7.
  • step #6 if necessary, until the proper pH level is achieved.
  • pH of raw distillate varies from batch to batch. Lower the TCS to a jacket temperature of 25° C. After the jacket temperature reaches 25° C, agitate for -5 minutes. Continue to lower the jacket temperature by 5° C increments, remembering to let agitate for -5 minutes for every temperature change until the JFR reaches a temperature of 10° C. After 10° C is achieved in the JFR, let agitate for -5 minutes at -10° C. Then add 0.001% of CBD seeds. After adding the seeds to the main body of the JFR, agitate for -15 minutes. a. Note (%) will come from total volume weight of distillate and solvent combined.
  • the CBD material in the JFR is now ready for solvent rinsing.
  • Removal is accomplished by utilizing vacuum pump control and vacuum rated glass collection vessels. Start pulling out the rinsing solvent by vacuum through the vacuum rated glass vessel and bottom valve until there is no more solvents exiting the JFR. Once the vacuum control lines in the vacuum rated glass collection vessels and lines connected to the bottom valve are empty, the JFR is then empty of residual solvent and ready for the rinse. Repeat steps 13 and 14 at least 4 times or until the majority of the CBD wet- isolate is white with a little pink color. Next, take a sample of the isolate and send it to the analytical lab for HPLC testing. The sample must have a purification of 99+% purity. If not, more solvent rinses are necessary. Once the purity level is reached, move to next step. Offloading and Purification proceeds immediately after proper purity level is achieved.
  • the CBD product resulting from the above process represents a substantial improvement over any known CBD product in every respect in relation to product efficacy, shelf life, and user tolerance.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de production d'un isolat de CBD à efficacité améliorée non adultéré pour une utilisation optimisée dans un inhalateur-doseur.
PCT/US2022/073669 2021-07-26 2022-07-13 Procédé de production d'isolat de cbd Ceased WO2023015102A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163259574P 2021-07-26 2021-07-26
US63/259,574 2021-07-26
US202217712091A 2022-04-02 2022-04-02
US17/712,091 2022-04-02

Publications (1)

Publication Number Publication Date
WO2023015102A1 true WO2023015102A1 (fr) 2023-02-09

Family

ID=85156394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/073669 Ceased WO2023015102A1 (fr) 2021-07-26 2022-07-13 Procédé de production d'isolat de cbd

Country Status (1)

Country Link
WO (1) WO2023015102A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2019100168A1 (fr) * 2017-11-27 2019-05-31 Enrico BOUCHARD Procédé de préparation d'une boisson terpénique à base de cannabis et boisson associée
US20190201809A1 (en) * 2015-01-22 2019-07-04 Phytoplant Research S.L. Methods of Purifying Cannabinoids Using Liquid:Liquid Chromatography
US20190307695A1 (en) * 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
US20210101856A1 (en) * 2019-09-20 2021-04-08 Marquette Analytica Cannabinoid processing methods and systems
US20210177914A1 (en) * 2019-12-11 2021-06-17 Cannabis Global, Inc. Cannabinoid enriched composition and method of using

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072939A1 (en) * 2005-06-16 2007-03-29 Euro-Celtique, S.A. Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20190201809A1 (en) * 2015-01-22 2019-07-04 Phytoplant Research S.L. Methods of Purifying Cannabinoids Using Liquid:Liquid Chromatography
WO2019100168A1 (fr) * 2017-11-27 2019-05-31 Enrico BOUCHARD Procédé de préparation d'une boisson terpénique à base de cannabis et boisson associée
US20190307695A1 (en) * 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
US20210101856A1 (en) * 2019-09-20 2021-04-08 Marquette Analytica Cannabinoid processing methods and systems
US20210177914A1 (en) * 2019-12-11 2021-06-17 Cannabis Global, Inc. Cannabinoid enriched composition and method of using

Similar Documents

Publication Publication Date Title
McARTHUR The identification of pituitary interstitial cell stimulating hormone in human urine
KR102593901B1 (ko) 제약-등급 20-히드록시엑디손 추출물, 그의 용도 및 그의 제법
DK165902B (da) Etoposid-praeparat
WO2023015102A1 (fr) Procédé de production d'isolat de cbd
WO2023009442A1 (fr) Procédé pour cbg # 10 équilibré en ph
CN101708177B (zh) 一种含多西他赛的药物组合物及其制备方法
CN116650471B (zh) 桑色素的新用途、及其自乳化给药系统和制备方法
CN113087758B (zh) 源自蔓菁的碳环化合物的衍生物及其应用
CN115487141B (zh) 一种布美他尼注射液组合物及其制备方法
US8815299B2 (en) Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds
WO2022135331A1 (fr) Composition pharmaceutique liquide stable contenant un composé de saponine de kuding
CN110015950A (zh) 制备醇乙氧基化物的方法及产品
CN121154650A (en) Progesterone preparation composition and preparation method thereof
Dorchy et al. Permanent neonatal diabetes mellitus: A case report with plasma insulin studies
CZ20021589A3 (cs) Deriváty ß-D-5-thioxylózy, způsob jejich přípravy a jejich terapeutické pouľití
CN102134236B (zh) 微细克拉霉素粉体的制备方法
WO2012019930A1 (fr) Méthode de traitement des stéatoses hépatiques et, en particulier, de la stéatohépatite non alcoolique
CN118459617A (zh) 一种延缓生殖衰老的复方多糖组合物的制备方法和应用
CA2498095C (fr) Procede d'obtention d'un melange naturel d'oestrogenes equins conjugues appauvris en composes lipophiles non conjugues
RU2777008C2 (ru) Состав hc-1119, способ его получения и применение
US10391419B1 (en) Isolation and purification of conjugated estrogens
WO2025252965A1 (fr) Composés dérivés de phragmaline destinés à être utilisés dans le traitement et/ou la prévention d'une maladie et/ou d'un trouble métabolique
TW201707709A (zh) 麥角固醇之用途
CN107903253A (zh) 一种化合物、合成路线及其在制备预防/治疗类风湿性关节炎药物中的应用
WO2025163156A1 (fr) Phytoecdysones et/ou dérivés de 20-hydroxyecdysone en combinaison avec un agoniste de glp-1 pour leur utilisation dans le traitement de l'obésité et du surpoids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22854021

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 11/06/2024)

122 Ep: pct application non-entry in european phase

Ref document number: 22854021

Country of ref document: EP

Kind code of ref document: A1